-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Beta Bionics, Raises Price Target to $33

Benzinga·10/29/2025 18:00:45
Listen to the news
Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $26 to $33.